LifeNet Health LifeSciences
Bud Brame has a extensive work experience in the healthcare industry, particularly in tissue services and product planning. Bud currently holds the position of Vice President of Corporate Reimbursement and General Manager, Biospecimens Research at LifeNet Health LifeSciences, a role they started in January 2022. Prior to this, Bud Brame worked at LifeNet Health for over three decades, holding various leadership positions. From 2015 onward, they served as Vice President of Strategic Product Planning and Reimbursement Services. Bud was also the VP and General Manager of the Skin and Wound Allograft Institute from 2007 to 2015. Before that, they served as VP of Tissue Services from 2007 to 2013 and as Vice-President of Tissue Operations from 1990 to 2007.
Bud Brame completed their Bachelor of Science degree in Medical Technology from Old Dominion University between 1978 and 1982. Bud went on to earn their Master of Business Administration (MBA) degree from Averett University, with their education taking place from 1997 to 1999.
This person is not in any teams
LifeNet Health LifeSciences
Driven by Innovation. Grounded by Mission. LifeNet Health LifeSciences meets the demand for human primary cells, tissues, and 3D models for scientific research, drug discovery, and safety testing. Our unprecedented access to donors and our unwavering commitment to honoring the donor gift lead to high-quality, human-relevant research solutions that accelerate discovery and optimize outcomes for future generations. Changing Science. Accelerating Discovery. Optimizing Outcomes. LifeNet Health LifeSciences leads the way in human in vitro biology for both non-diseased and diseased research needs. LifeSciences combines innovative, technology-driven research and development programs to create human tissue and cell-based research products and services. Why Us? We meet the demand for primary human cells, human tissues, and optimized media for scientific research, drug discovery, and safety testing. The application of 3D human cellular models and the use of human-derived hydrogels enables significant scientific improvements for precise biologic experiments. Our growing portfolio of best-in-class solutions expedites the research curve and enables the scientific community to develop and fine-tune new, safe therapies.